Abstract
Despite the limitations of the positron emission tomography/computed tomography method using radiopharmaceutical 18F-Fluorodeoxyglucose (18F-FDG PET/CT), i.e. non-specific properties of the radiopharmaceutical 18F-FDG and high costs and low PET/CT study availability, several authors indicate the 18F-FDG PET/CT technique as the most useful in detection, staging and planning treatment of the oesophageal malignancies.
References
Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, et al. Oesophageal Cancer. Nat Rev Dis Primers. 2017;3:17048.
Foley K, Findlay J, Goh V. Novel imaging techniques in staging oesophageal cancer. Best Pract Res Clin Gastroenterol. 2018;36-37:17-25.
Wang WP, Ni PZ, Yang YS, He SL, Hu WP, et al. The Role and Prognostic Significance of Aortopulmonary, Anterior Mediastinal, and Tracheobronchial Lymph Nodes in Oesophageal Cancer: Update of the Eighth-Edition TNM Staging System (2018). Ann Surg Oncol. 2019;26:1005-11.
Fatima N, Zaman MU, Zaman A, Zaman U, Tasheen R, et al. Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using 18FDG PET/CT with Standardized Protocol. Asian Pac J Cancer Prev. 2019; 20: 2003-8.
Ogino I, Watanabe S, Hirasawa K, Misumi T, Hata M, et al. The Importance of Concurrent Chemotherapy for T1 Esophageal Cancer: Role of FDG-PET/CT for Local Control. In vivo. 2018; 32: 1269-74.
Tsuchitani T, Takahashi Y, Maeda Y, Oda M, Enoki T, et al. Investigation of appropriate semi-quantitative index for assessment of esophageal and breast cancer treatment response in Japanese patients using 18F-FDG PET/CT findings.
Hell J Nucl Med. 2019; 22: 20-4.
Martenka P. Ocena najnowszych trendów w diagnozowaniu i leczeniu nowotworów złośliwych górnego odcinka układu pokarmowego na rok 2014 wg doniesień prezentowanych podczas konferencji ASTRO 56 w San Francisco.
Letters in Oncology Science 2017;14:80-5.
Cuellar SLB, Palacio DP, Beneveniste MF, Carter BW, Hofstetter WL, et al. Positron Emission Tomography/Computed Tomography in Esophageal Carcinoma: Applications and Limitations. Semin Ultrasound CT MRI. 2017;38:571-83.
Jeong DY, Kim MY, Lee KS, Choi JY, Kim SJ, et al. Surgically resected
T1-and T2-stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CT. Cancer Med. 2018;00:1-10.
Offman J, Pesola F, Sasieni P. Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037.
Br J Cancer. 2018;118:1391-8.
Old OJ, Isabelle M, Barr H. Chapter 9. Staging Early Esophageal Cancer. Rozdz w: Jansen M, Wright NA. Stem Cells, Pre-neoplasia and Early Cancer of the Upper Gastrointestinal Tract, Advances in Experimental Medicine and Biology 908. Springer International Publishing Switzerland 2016;161-81.
Goel R, Subramaniam RM, Wachsmann JW. PET/Computed Tomography Scanning and Precision Medicine. Esophageal Cancer. PET Clin. 2017: 11-12.
Dong Y, Wei Y, Chen G, Huang Y, Song P, et al. Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [18F]Alfatide versus [18F]FDG. Mol Imaging Biol. 2019;21:175-81.
Dellaportas D, Zylstra J, Gossage J, Baker C, Kelly M, et al. The Prognostic Role of Pre-operative Positron Emission Tomography-Computed Tomography and Endoscopic Ultrasound Parameters in Oesophageal Adenocarcinoma. Chirurgia. 2019;114: 443-50.
Pietrzak AK, Martenka P, Strzesak E, Wierzchosławska E, Marszałek A, et al. Will Rogers phenomenon in the oesophageal cancer patients staging – CT versus 18F-FDG PET/CT: retrospective study. Hell J Nucl Med. 2019;22(Supp 2):174-80.
Walker MJ, Rogers W. Defining disease in the context of overdiagnosis.
Med Health Care Philos. 2017;20:269-80.
Lee NCJ, Eskander A, Park HS, Mehra S, Burtness MA, et al. Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Cancer. 2019:125:2975-8.